Lumen Integrates with Connect IQ to Provide Garmin Users Metabolic Data to Improve Their Performance and Health
11.11.2020 13:00:00 EET | Business Wire | Press release
Lumen, the world’s first hand-held metabolic tracking device, together with Garmin® International, Inc., a unit of Garmin Ltd. (NASDAQ: GRMN), have launched a Connect IQ Lumen App and Garmin Health API integration, allowing users to better understand the impact of fitness and nutrition decisions on their body in real time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201111005049/en/
Lumen and Garmin integration (Photo: Lumen)
Through the CO2 concentration in a single breath, Lumen measures your metabolic health and provides daily personalised nutrition plans and insights into what your body is burning - fats or carbs. Lumen supports fat burn and improves your metabolic flexibility, which is your body's ability to efficiently switch between using carbs and fats as a fuel source.
Garmin activity trackers and smartwatches help you track and share your activities. Thanks to Lumen data and the Garmin Health API integration, Garmin users can now seamlessly integrate their health and activity data such as heart rate, sleep, steps and calories burned, into the Lumen app and instantly optimise their fitness journey.
“We are thrilled to work with Garmin on this crucial integration. We know how important it is for our users to get valuable insights into their fitness and this will allow them to make more informed decisions about their nutrition and improve their metabolic health,” said Lumen CEO, Daniel Tal.
By combining Garmin and Lumen data, users will be able to monitor their carb fuel consumption through notifications that guide them on when to breathe into Lumen and unlock their day or take a post workout breath. Users can now see how their workout affects their metabolism through recovery macros and a comprehensive Garmin workout summary.
“Lumen is an innovative organisation pushing the boundaries on metabolic health and performance optimisation. Garmin’s Connect IQ platform will enable users to act in real-time to make the right fitness and nutrition decisions at every moment,” said Sean McNamara, Garmin Health Senior Manager Sales and Marketing.
For continual metabolic tracking, Garmin users with compatible devices will also have access to crucial Lumen data such as morning insights, daily and weekly Lumen levels and the Lumen Flex Score which indicates the degree of metabolic flexibility. The goal is to make sure that nutrition and metabolic health remain top of mind.
About Garmin Health
Engineered on the inside for life on the outside, Garmin products have revolutionised the wellness industry. Garmin Health provides enterprise solutions that leverage Garmin wearables and the high-quality sensor data they produce for applications in the corporate wellness, population health, and patient monitoring markets. For more information, visit garmin.com/health, contact the Media Relations department at 913-397-8200, or follow us at facebook.com/garmin, twitter.com/garminnews, instagram.com/garminwellness or youtube.com/garmin.
About Garmin Connect IQ
Connect IQ is the app system for Garmin wearables, bike computers, and outdoor handhelds. Connect IQ allows developers to create on-device solutions for Garmin users. Developers use the Connect IQ SDK to develop apps, and then upload their creations to the Connect IQ store. From there, millions of Garmin users can browse thousands of apps including Starbucks, Spotify, and Amazon Music for download to their Connect IQ compatible device.
About Lumen
Lumen is a device and app that measures your metabolism in a single breath through a complex algorithm and provides daily personalised nutrition based on your metabolic data. At Lumen, we believe that a healthy metabolism is the key to better health, and that everyone can attain it with a little help from Lumen.
Founded in 2014 by scientists and experienced entrepreneurs, Lumen is the biggest metabolic measurement platform in the world, with over 1,000,000 measurements per month. Lumen’s vision is to improve the world's metabolic health and quality of life by empowering individuals to make smarter decisions about their nutrition and lifestyle. Our technology provides individuals with new metrics on metabolism and a system to keep them accountable so they can achieve their health and wellness goals and prevent long-term chronic illness by improving their metabolic health.
Follow us at twitter.com/LumenMetabolism, facebook.com/Lumen.me/, instagram.com/lumen.me/, youtube.com/c/Lumendotme
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201111005049/en/
Contact information
Press
press@lumen.me
+972548161939
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom